Metallothioneins in Prion-and Amyloid-Related Diseases

Journal of Alzheimer's Disease

Volumn 51, Issue 3, 2016, Pages 637-656

  Adam, Pavlína ^a,b   Křížková, Soňa ^a,b   Heger, Zbyněk ^a,b   Babula, Petr ^c   Pekařík, Vladimír ^a,b   Vaculovičová, Markéta ^a,b   Gomes, Cláudio M ^d   Kizek, René ^a,b   Adam, Vojtěch ^a,b  

^a MENDEL UNIVERSITY IN BRNO   (Czech Republic)

^b BRNO UNIVERSITY OF TECHNOLOGY   (Czech Republic)

^c MASARYK UNIVERSITY   (Czech Republic)

^d UNIVERSITY OF LISBON   (Portugal)

Author keywords

Alzheimer's disease; brain; copper; metallothionein; neurodegenerative disorders; prion protein

Indexed keywords

GROWTH INHIBITOR; HEAVY METAL; METALLOTHIONEIN; METALLOTHIONEIN I; METALLOTHIONEIN II; METALLOTHIONEIN III; REACTIVE OXYGEN METABOLITE;

AMYLOIDOSIS; CYTOTOXICITY; ENDOPLASMIC RETICULUM; ENERGY EXPENDITURE; HOMEOSTASIS; HUMAN; IMMUNOREACTIVITY; MENTAL STRESS; MITOCHONDRIAL MEMBRANE; MOLECULAR WEIGHT; NONHUMAN; PRION DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN PROCESSING; REVIEW; ANIMAL; BRAIN DISEASE; METABOLISM;

AMYLOIDOSIS; ANIMALS; BRAIN DISEASES; HUMANS; METALLOTHIONEIN; PRION DISEASES;

EID: 84963757777     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-150984     Document Type: Review

References (181)

1. Bolton DC, McKinley MP, Prusiner SB (1982) Identification of a protein that purifies with the scrapie prion. Science 218, 1309-1311.
2. Prusiner SB (1998) Prions. Proc Natl Acad Sci U S A 95, 13363-13383.
3. Imran M, Mahmood S (2011) An overviewof human prion diseases. Virol J 8, 1-9.
4. Stohr J, Watts JC, Mensinger ZL, Oehler A, Grillo SK, DeArmond SJ, Prusiner SB, Giles K (2012) Purified and synthetic Alzheimer's amyloid beta (A beta) prions. Proc Natl Acad Sci U S A 109, 11025-11030.
5. Polymenidou M, Cleveland DW (2012) Prion-like spread of protein aggregates in neurodegeneration. J Exp Med 209, 889-893.
6. Munch C, Bertolotti A (2012) Propagation of the prion phenomenon: Beyond the seeding principle. J Mol Biol 421, 491-498.
7. Nieznanski K, Choi JK, Chen SG, Surewicz K, Surewicz WK (2012) Soluble prion protein inhibits Amyloid-beta (A beta) fibrillization and toxicity. J Biol Chem 287, 33104-33108.
8. de Calignon A, Polydoro M, Suarez-Calvet M,William C, Adamowicz DH, Kopeikina KJ, Pitstick R, Sahara N, Ashe KH, Carlson GA, Spires-Jones TL, Hyman BT (2012) Propagation of tau pathology in a model of early Alzheimer's disease. Neuron 73, 685-697.
9. Liu L, Drouet V, Wu JW, Witter MP, Small SA, Clelland C, Duff K (2012) Trans-synaptic spread of tau pathology in vivo. PLoS One 7, 1-9.
10. Luk KC,Kehm VM, Zhang B, O'Brien P, Trojanowski JQ, LeeVMY(2012) Intracerebral inoculation of pathological alpha-synuclein initiates a rapidly progressive neurodegenerative alpha-synucleinopathy in mice. J Exp Med 209, 975-986.
11. Mougenot AL, Nicot S, Bencsik A, Morignat E, Verchere J, Lakhdar L, Legastelois S, Baron T (2012) Prion-like acceleration of a synucleinopathy in a transgenic mouse model. Neurobiol Aging 33, 2225-2228.
12. Kanouchi T, Ohkubo T, Yokota T (2012) Can regional spreading of amyotrophic lateral sclerosis motor symptoms be explained by prion-like propagation? J Neurol Neurosurg Psychiatry 83, 739-745.
13. Moore RC, Xiang FQ, Monaghan J, Han D, Zhang ZP, Edstrom L, Anvret M, Prusiner SB (2001) Huntington disease phenocopy is a familial prion disease. Am J Hum Genet 69, 1385-1388.
14. Costanzo M, Zurzolo C (2013) The cell biology of prion-like spread of protein aggregates: Mechanisms and implication in neurodegeneration. Biochem J 452, 1-17.
15. Hozumi I, Asanuma M,Yamada M, UchidaY(2004) Metallothioneins and neurodegenerative diseases. J Health Sci 50, 323-331.
16. Sogawa CA, Asanuma M, Sogawa N, Miyazaki I, Nakanishi T, Furuta H, OgawaN(2001) Localization, regulation, and function of metallothionein-III/growth inhibitory factor in the brain. Acta Med Okayama 55, 1-9.
17. Kawashima T, Doh-ura K, Torisu M, Uchida Y, Furuta A, Iwaki T (2000) Differential expression of metallothioneins in human prion diseases. Dement Geriatr Cogn Disord 11, 251-262.
18. Barnham KJ, Masters CL, Bush AI (2004) Neurodegenerative diseases and oxidative stress. Nat Rev Drug Discov 3, 205-214.
19. Margoshes M, Vallee BL (1957) A cadmium protein from equine kidney cortex. J Am Chem Soc 79, 4813-4814.
20. Kagi JHR (1991) Overview of metallothionein. Methods Enzymol 205, 613-626.
21. Blindauer CA (2011) Bacterial metallothioneins: Past, present, and questions for the future. J Biol Inorg Chem 16, 1011-1024.
22. HamerDH(1986) Metallothionein. Annu Rev Biochem 55, 913-951.
23. Binz PA, Kagi JHR (1999) Metallothionein: Molecular evolution and classification In Metallothionein IV, Klaassen CD, ed. Birkhauser Basel, Basel, pp. 7-13.
24. Coyle P, Philcox JC, Carey LC, Rofe AM (2002) Metallothionein: The multipurpose protein. Cell Mol Life Sci 59, 627-647.
25. Moffatt P, Denizeau F (1997) Metallothionein in physiological and physiopathological processes. Drug Metab Rev 29, 261-307.
26. Babula P, Masarik M, Adam V, Eckschlager T, Stiborova M, Trnkova L, Skutkova H, Provaznik I, Hubalek J, Kizek R (2012) Mammalian metallothioneins: Properties and functions. Metallomics 4, 739-750.
27. Vasak M, Meloni G (2011) Chemistry and biology of mammalian metallothioneins. J Biol Inorg Chem 16, 1067-1078.
28. Babula P, Kohoutkova V, Opatrilova R, Dankova I, Masarik M, Kizek R (2010) Pharmaceutical importance of zinc and metallothionein in cell signalling. Chim Oggi-Chem Today 28, 18-21.
29. Kozlowski H, Janicka-Klos A, Brasun J, Gaggelli E, Valensin D, Valensin G (2009) Copper, iron, and zinc ions homeostasis and their role in neurodegenerative disorders (metal uptake, transport, distribution and regulation). Coord Chem Rev 253, 2665-2685.
30. Erickson JC, Hollopeter G, Thomas SA, Froelick GJ, Palmiter RD (1997) Disruption of the metallothionein-III gene in mice: Analysis of brain zinc, behavior, and neuron vulnerability to metals, aging, and seizures. J Neurosci 17, 1271-1281.
31. Chung RS, Penkowa M, Dittmann J, King CE, Bartlett C, Asmussen JW, Hidalgo J, Carrasco J, Leung YKJ, Walker AK, Fung SJ, Dunlop SA, Fitzgerald M, Beazley LD, Chuah MI, Vickers JC, West AK (2008) Redefining the role of metallothionein within the injured brain: Extracellular metallothioneins play an important role in the astrocyte-neuron response to injury. J Biol Chem 283, 15349-15358.
32. Deloncle R, Guillard O, Bind JL, Delaval J, Fleury N, Mauco G, Lesage G (2006) Free radical generation of protease-resistant prion after substitution of manganese for copper in bovine brain homogenate. Neurotoxicology 27, 437-444.
33. Valko M, Morris H, Cronin MTD (2005) Metals, toxicity and oxidative stress. Curr Med Chem 12, 1161-1208.
34. Jomova K, Vondrakova D, Lawson M, Valko M (2010) Metals, oxidative stress and neurodegenerative disorders. Mol Cell Biochem 345, 91-104.
35. Uchida Y, Takio K, Titani K, Ihara Y, Tomonaga M (1991) The growth inhibitory factor that is deficient in the Alzheimers-disease brain is a 68-amino acid metallothionein-like Protein. Neuron 7, 337-347.
36. Palmiter RD, Findley SD, Whitmore TE, Durnam DM (1992) MT-III, a brain-specific member of the metallothionein gene family Proc Natl Acad Sci U S A 89, 6333-6337.
37. Irie Y, Mori F, Keung WM, Mizushima Y, Wakabayashi K (2004) Expression of neuronal growth inhibitory factor (Metallothionein-III) in the salivary gland. Physiol Res 53, 719-723.
38. Hoey JG, Garrett SH, Sens MA, Todd JH, Sens DA (1997) Expression of MT-3 mRNA in human kidney, proximal tubule cell cultures and renal cell carcinoma. Toxicol Lett 92, 149-160.
39. Moffatt P, Seguin C (1998) Expression of the gene encoding metallothionein-3 in organs of the reproductive system DNA Cell Biol 17, 501-510.
40. Garrett SH, Sens MA, Todd JH, Somji S, Sens DA (1999) Expression of MT-3 protein in the human kidney. Toxicol Lett 105, 207-214.
41. Tuzel E, Kirkali Z, Yorukoglu K, Mungan MU, Sade M (2001) Metallothionein expression in renal cell carcinoma: Subcellular localization and prognostic significanceJUrol 165, 1710-1713.
42. Deng DJ, El-Rifai W, Ji JF, Zhu BD, Trampont P, Li JY, Smith MF, Powel SM (2003) Hypermethylation of metallothionein-3 CpG island in gastric carcinoma. Cancerogenesis 24, 25-29.
43. Kmiecik AM, Pula B, Suchanski J, Olbromski M, Gomulkiewicz A, Owczarek T, Kruczak A, Ambicka A, Rys J, Ugorski M, Podhorska-Okolow M, Dziegiel P (2015) Metallothionein-3 increases triple-negative breast cancer cell invasiveness via induction of metalloproteinase expression. PLoS One 10, 1-6.
44. Artells E, Palacios O, Capdevila M, Atrian S (2014) In vivo-folded metal-metallothionein 3 complexes reveal the Cu-thioneinratherthanZn-thioneincharacter of this brainspecific mammalian metallothionein. FEBS J 281, 1659-1678.
45. Sewell AK, Jensen LT, Erickson JC, Palmiter RD, Winge DR (1995) Bioactivity of metallothionein-3 correlates with its novel beta-domain sequence rather than metalbinding properties Biochemistry 34, 4740-4747.
46. Bogumil R, Faller P, Pountney DL, Vasak M (1996) Evidence for Cu(I) clusters and Zn(II) clusters in neuronal growth-inhibitory factor isolated from bovine brain. Eur J Biochem 238, 698-705.
47. Hasler DW, Faller P, Vasak M (1998) Metal-thiolate clusters in the C-terminal domain of human neuronal growth inhibitory factor (GIF). Biochemistry 37, 14966-14973.
48. Toriumi S, Saito T, Hosokawa T, Takahashi Y, Numata T, Kurasaki M (2005) Metal binding ability of metallothionein-3 expressed in Escherichia coli. Basic Clin Pharmacol Toxicol 96, 295-301.
49. Bogumil R, Faller P, Binz PA, Vasak M, Charnock JM, Garner CD (1998) Structural characterization of Cu(I) and Zn(II) sites in neuronal-growth-inhibitory factor by extended X-ray absorption fine structure (EXAFS). Eur J Biochem 255, 172-177.
50. Hartmann HJ, Morpurgo L, Desideri A, Rotilio G, Weser U (1983) Reconstitution of stellacyanin as a case of direct Cu(I) transfer between yeast copper thionein and blue copper apoprotein. FEBS Lett 152, 94-96.
51. Morpurgo L, Hartmann HJ, Desideri A, Weser U, Rotilio G (1983) Yeast copper-thionein can reconstitute the japanese-lacquer-tree (rhus vernicifera) laccase from the type-2-copper-depleted enzyme via a direct copper(I)-transfer mechanism. Biochem J 211, 515-517.
52. Howells C,West AK, Chung RS (2010) Neuronal growthinhibitory factor (metallothionein-3): Evaluation of the biological function of growth-inhibitory factor in the injured and neurodegenerative brain. FEBS J 277, 2931-2939.
53. Meloni G, Faller P, Vasak M (2007) Redox silencing of copper in metal-linked neurodegenerative disorders reaction of Zn(7)metallothionein-3 with Cu2+ions. J Biol Chem 282, 16068-16078.
54. Takeda A, Fujii H, Minamino T, Tamano H (2014) Intracellular Zn2+signaling in cognition. J Neurosci Res 92, 819-824.
55. Orihuela R, Fernandez B, Palacios O, Valero E, Atrian S, Watt RK, Dominguez-Vera JM, Capdevila M (2011) Ferritin and metallothionein: Dangerous liaisons. Chem Commun 47, 12155-12157.
56. Shi YB, Du L, Zheng WJ, Tang WX (2002) Isolation of GIF from porcine brain and studies of its zinc transfer kinetics with apo-carbonic anhydrase. Biometals 15, 421-427.
57. Chen Y, Irie Y, Keung WM, Maret W (2002) S-nitrosothiols react preferentially with zinc thiolate clusters of metallothionein III through transnitrosation. Biochemistry 41, 8360-8367.
58. Knipp M, Meloni G, Roschitzki B, Vasak M (2005) Zn(7)metallothionein-3 and the synaptic vesicle cycle: Interaction of metallothionein-3 with the small GTPase Rab3A. Biochemistry 44, 3159-3165.
59. Martin BL, Tokheim AM, McCarthy PT, Doms BS, Davis AA, Armitage IM (2006) Metallothionein-3 and neuronal nitric oxide synthase levels in brains from the Tg2576 mouse model of Alzheimer's disease. Mol Cell Biochem 283, 129-137.
60. Lee SJ, Park MH, Kim HJ, Koh JY (2010) Metallothionein-3 regulates lysosomal function in cultured astrocytes under both normal and oxidative conditions. Glia 58, 1186-1196.
61. Kim EY, Koh JY, Kim YH, Sohn S, Joe E, Gwag BJ (1999) Zn2+ entry produces oxidative neuronal necrosis in cortical cell cultures. Eur J Neurosci 11, 327-334.
62. Watjen W, Haase H, Biagioli M, Beyersmann D (2002) Induction of apoptosis in mammalian cells by cadmium and zinc. Environ Health Perspect 110, 865-867.
63. Koh JY (2001) Zinc and disease of the brain. Mol Neurobiol 24, 99-106.
64. Lu H, Pang W, Hu YD, Yang HP, Huang CY, Jiang YG (2011) Effects of intracellular zinc depletion on the expression of VDAC in cultured hippocampal neurons. Nutr Neurosci 14, 80-87.
65. Pang W, Lu H, Hu YD, Yang HP, Leng X, Jiang YG (2012) Depletion of intracellular zinc induced apoptosis in cultured hippocampal neurons through Raf/MEK/ERK pathways. Nutr Neurosci 15, 18-24.
66. Truong-TranAQ, Carter J, Ruffin RE, Zalewski PD (2001) The role of zinc in caspase activation and apoptotic cell death. Biometals 14, 315-330.
67. Lee JM, Kim KR, Im H, Kim YH (2015) Zinc preconditioning protects against neuronal apoptosis through the mitogen-activated protein kinase-mediated induction of heat shock protein 70. Biochem Biophys Res Commun 459, 220-226.
68. Pang W, Leng X, Lu H, Yang HP, Song N, Tan L, Jiang YG, Guo CJ (2013) Depletion of intracellular zinc induces apoptosis of cultured hippocampal neurons through suppression of ERK signaling pathway and activation of caspase-3. Neurosci Lett 552, 140-145.
69. Santos CR, Martinho A, Quintela T, Gonçalves I (2012) Neuroprotective and neuroregenerative properties of metallothioneins. IUBMB Life 64, 126-135.
70. Somji S, Garrett SH, Sens MA, Gurel V, Sens DA (2004) Expression of metallothionein isoform 3 (MT-3) determines the choice between apoptotic or necrotic cell death in Cd+2-exposed human proximal tubule cells. Toxicol Sci 80, 358-366.
71. Yamada M, Hayashi S, Hozumi I, Inuzuka T, Tsuji S, Takahashi H (1996) Subcellular localization of growth inhibitory factor in rat brain: Light and electron microscopic immunohistochemical studies. Brain Res 735, 257-264.
72. Lahti DW, Hoekman JD, Tokheim AM, Martin BL, Armitage IM (2005) Identification of mouse brain proteins associated with isoform 3 of metallothionein. Protein Sci 14, 1151-1157.
73. El Ghazi I, Martin BL, Armitage IM (2011) New proteins found interacting with brain metallothionein-3 are linked to secretion. Int J Alzheimers Dis 2011, 1-9.
74. Koumura A, Kakefuda K, Honda A, Ito Y, Tsuruma K, Shimazawa M, Uchida Y, Hozumi I, Satoh M, Inuzuka T, Hara H (2009) Metallothionein-3 deficient mice exhibit abnormalities of psychological behaviors. Neurosci Lett 467, 11-14.
75. Byun HR, Kim DK, Koh JY (2011) Obesity and downregulated hypothalamic leptin receptors in male metallothionein-3-null mice. Neurobiol Dis 44, 125-132.
76. Dou X, Tian X, Zheng YY, Huang JL, Shen ZL, Li HX, Wang XL, Mo FF, Wang WY, Wang S, Shen H (2014) Psychological stress induced hippocampus zinc dyshomeostasis and depression-like behavior in rats. Behav Brain Res 273, 133-138.
77. Galecki P, Talarowska M, Bobinska K, Kowalczyk E, Galecka E, Lewinski A (2013) Thiol protein groups correlate with cognitive impairment in patients with recurrent depressive disorder. Neuroendocrinol Lett 34, 780-786.
78. Irie Y (2008) Eugenol : A new antidepressant in Phytopharmacology and Therapeutic Values II, Govil JN, Singh VK, Mishra SK, eds. Studium Press LLC, Houston, pp. 135-146.
79. Irie Y, Itokazu N, Anjiki N, Ishige A,Watanabe K, Keung WM (2004) Eugenol exhibits antidepressant-like activity in mice and induces expression of metallothionein-III in the hippocampus. Brain Res 1011, 243-246.
80. Bolognin S, Cozzi B, Zambenedetti P, Zatta P (2014) Metallothioneins and the central nervous system: From a deregulation in neurodegenerative diseases to the development of new therapeutic approaches. J Alzheimers Dis 41, 29-42.
81. Gaggelli E, Kozlowski H, Valensin D, Valensin G (2006) Copper homeostasis and neurodegenerative disorders (Alzheimer's, prion, and Parkinson's diseases and amyotrophic lateral sclerosis). Chem Rev 106, 1995-2044.
82. Cuajungco MP, Lees GJ (1997) Zinc metabolism in the brain: Relevance to human neurodegenerative disorders. Neurobiol Dis 4, 137-169.
83. Tiwari MN, Agarwal S, Bhatnagar P, Singhal NK, Tiwari SK, Kumar P, Chauhan LKS, Patel DK, Chaturvedi RK, Singh MP, Gupta KC (2013) Nicotineencapsulated poly(lactic-co-glycolic) acid nanoparticles improve neuroprotective efficacy against MPTP-induced parkinsonism. Free Radic Biol Med 65, 704-718.
84. Pedersen JT, Hureau C, Hemmingsen L, Heegaard NH, Ostergaard J, Vasak M, Faller P (2012) Rapid exchange of metal between Zn-7-metallothionein-3 and amyloidbeta peptide promotes amyloid-related structural changes. Biochemistry 51, 1697-1706.
85. Heneka MT, O'Banion MK, Terwel D, Kummer MP (2010) Neuroinflammatory processes in Alzheimer's disease. J Neural Transm 117, 919-947.
86. Chen JH, Ke KF, Lu JH, Qiu YH, Peng YP (2015) Protection of tgf-beta 1 against neuroinflammation and neurodegeneration in a beta(1-42)-induced Alzheimer's disease model rats. PLoS One 10, 1-19.
87. Manso Y, Carrasco J, Comes G, Adlard PA, Bush AI, Hidalgo J (2012) Characterization of the role of the antioxidant proteins metallothioneins 1 and 2 in an animal model of Alzheimer's disease. Cell Mol Life Sci 69, 3665-3681.
88. Zhang J, Ke KF, Liu Z, Qiu YH, Peng YP (2013) Th17 Cell-Mediated Neuroinflammation Is Involved in Neurodegeneration of A1-42-induced Alzheimer's disease model rats. PLoS One 8, 1-9.
89. Lee JY, Cole TB, Palmiter RD, Suh SW, Koh JY (2002) Contribution by synaptic zinc to the gender-disparate plaque formation in human Swedish mutant APP transgenic mice. Proc Natl Acad Sci U S A 99, 7705-7710.
90. De Ricco R, Valensin D, Dell'Acqua S, Casella L, Hureau C, Faller P (2015) Copper(I/II), alpha/beta-Synuclein and Amyloid-β: Menage a trois? ChemBioChem 16, 2319-2328.
91. Faller P, Hureau C, La Penna G (2014) Metal ions and intrinsically disordered proteins and peptides: From Cu/Zn Amyloid-β to general principles. Acc Chem Res 47, 2252-2259.
92. Halliwell B, Gutteridge JMC (1984) Oxygen-toxicity, oxygen radicals, transition-metals and disease. Biochem J 219, 1-14.
93. Manso Y, Carrasco J, Comes G, Meloni G, Adlard PA, Bush AI, Vasak M, Hidalgo J (2012) Characterization of the role of metallothionein-3 in an animal model of Alzheimer's disease. Cell Mol Life Sci 69, 3683-3700.
94. Dawson TM, Dawson VL (2003) Molecular pathways of neurodegeneration in Parkinson's disease. Science 302, 819-822.
95. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, GoedertM(1997) Alpha-synuclein in Lewy bodies. Nature 388, 839-840.
96. Paik SR, Shin HJ, Lee JH (2000) Metal-catalyzed oxidation of alpha-synuclein in the presence of copper(II) and hydrogen peroxide. Arch Biochem Biophys 378, 269-277.
97. Binolfi A, Lamberto GR, Duran R, Quintanar L, Bertoncini CW, Souza JM, Cervenansky C, Zweckstetter M, Griesinger C, Fernandez CO (2008) Site-specific interactions of Cu(II) with alpha and beta-synuclein: Bridging the molecular gap between metal binding and aggregation. J Am Chem Soc 130, 11801-11812.
98. Drew SC, Leong SL, Pham CL, Tew DJ, Masters CL, Miles LA, Cappai R, Barnham KJ (2008) Cu2+binding modes of recombinant alpha-synuclein-insights fromEPR spectroscopy. J Am Chem Soc 130, 7766-7773.
99. Meloni G, Vasak M (2011) Redox activity of alphasynuclein-Cu is silenced by Zn-7-metallothionein-3. Free Radic Biol Med 50, 1471-1479.
100. Ma F, Wang H, Chen B, Wang F, Xu H (2011) Metallothionein 3 attenuated the apoptosis of neurons in the CA1 region of the hippocampus in the senescence-accelerated mouse/PRONE8 (SAMP8). Arq Neuropsiquiatr 69, 105-111.
101. Meloni G, Sonois V, Delaine T, Guilloreau L, Gillet A, Teissie J, Faller P, Vasak M (2008) Metal swap between Zn(7)-metallothionein-3 and amyloid-beta-Cu protects against amyloid-beta toxicity. Nat Chem Biol 4, 366-372.
102. Chung RS, Howells C, Eaton ED, Shabala L, Zovo K, Palumaa P, Sillard R,Woodhouse A, Bennett WR, Ray S, Vickers JC,West AK (2010) The native copper-and zincbinding protein metallothionein blocks copper-mediated Abeta aggregation and toxicity in rat cortical neurons. PLoS One 5, 1-11.
103. Adlard PA,West AK, Vickers JC (1998) Increased density of metallothionein I/II-immunopositive cortical glial cells in the early stages of Alzheimer's disease. Neurobiol Dis 5, 349-356.
104. Richarz AN, Bratter P (2002) Speciation analysis of trace elements in the brains of individuals with Alzheimer's disease with special emphasis on metallothioneins. Anal Bioanal Chem 372, 412-417.
105. Zambenedetti P, Giordano R, Zatta P (1998) Metallothioneins are highly expressed in astrocytes and microcapillaries in Alzheimer's disease. J Chem Neuroanat 15, 21-26.
106. Hozumi I, Yamada M, Uchida Y, Ozawa K, Takahashi H, Inuzuka T (2008) The expression of metallothioneins is diminished in the spinal cords of patients with sporadic ALS. Amyotroph Lateral Scler 9, 294-298.
107. Puttaparthi K, Gitomer WL, Krishnan U, Son M, Rajendran B, Elliott JL (2002) Disease progression in a transgenic model of familial amyotrophic lateral sclerosis is dependent on both neuronal and non-neuronal zinc binding proteins. J Neurosci 22, 8790-8796.
108. Jeong JK, Moon MH, Lee YJ, Seol JW, Park SY (2012) Translocation of cellular prion protein to non-lipid rafts protects human prion-mediated neuronal damage. Int J Mol Med 29, 387-392.
109. Quintanar L, Rivillas-Acevedo L, Grande-Aztatzi R, Gomez-Castro CZ, Arcos-Lopez T, Vela A (2013) Copper coordination to the prion protein: Insights from theoretical studies. Coord Chem Rev 257, 429-444.
110. Sobrova P, Ryvolova M, Hynek D, Adam V, Hubalek J, Kizek R (2012) Electrochemical behaviour of native and denatured beta-sheet breaker prion protein. Int J Electrochem Sci 7, 928-942.
111. D'Angelo P, Della Longa S, Arcovito A, Mancini G, Zitolo A, Chillemi G, Giachin G, Legname G, Benetti F (2012) Effects of the pathological Q212P mutation on human prion protein non-octarepeat copper-binding site. Biochemistry 51, 6068-6079.
112. Prusiner SB (1991) Molecular biology of prion diseases Science 252, 1515-1522.
113. Cavaliere P, Torrent J, Prigent S, Granata V, Pauwels K, Pastore A, Rezaei H, Zagari A (2013) Binding of methylene blue to a surface cleft inhibits the oligomerization and fibrillization of prion protein. Biochim Biophys Acta 1832, 20-28.
114. Holmes BB, Diamond MI (2012) Cellular mechanisms of protein aggregate propagation. Curr Opin Neurol 25, 721-726.
115. De Chiara G, Marcocci ME, Sgarbanti R, Civitelli L, Ripoli C, Piacentini R, Garaci E, Grassi C, Palamara AT (2012) Infectious agents and neurodegeneration. Mol Neurobiol 46, 614-638.
116. Kanthasamy AG, Choi C, Jin H, Harischandra DS, Anantharam V, Kanthasamy A (2012) Effect of divalent metals on the neuronal proteasomal system, prion protein ubiquitination and aggregation. Toxicol Lett 214, 288-295.
117. Brown DR, Qin KF, Herms JW, Madlung A, Manson J, Strome R, Fraser PE, Kruck T, von Bohlen A, Schulz-SchaefferW, Giese A,WestawayD, KretzschmarH(1997) The cellular prion protein binds copper in vivo. Nature 390, 684-687.
118. Kramer ML, Kratzin HD, Schmidt B, Romer A,Windl O, Liemann S, Hornemann S, Kretzschmar H (2001) Prion protein binds copper within the physiological concentration range. J Biol Chem 276, 16711-16719.
119. Hornshaw MP, McDermott JR, Candy JM, Lakey JH (1995) Copper-binding to the n-terminal tandem repeat region of mammalian and avian prion protein: Structural studies using synthetic peptides. Biochem Biophys Res Commun 214, 993-999.
120. Brown DR, Besinger A (1998) Prion protein expression and superoxide dismutase activity. Biochem J 334, 423-429.
121. Wong BS, Pan T, Liu T, Li RL, Gambetti P, Sy MS (2000) Differential contribution of superoxide dismutase activity by prion protein in vivo. Biochem Biophys Res Commun 273, 136-139.
122. Younan ND, Klewpatinond M,Davies P, RubanAV, Brown DR, Viles JH (2011) Copper(II)-induced secondary structure changes and reduced folding stability of the prion protein. J Mol Biol 410, 369-382.
123. Klewpatinond M, Davies P, Bowen S, Brown DR, Viles JH (2008) Deconvoluting the Cu(2+) binding modes of full-length prion protein J Biol Chem 283, 1870-1881.
124. Kenward AG, Bartolotti LJ, Burns CS (2007) Copper and zinc promote interactions between membrane-anchored peptides of the metal binding domain of the prion protein Biochemistry 46, 4261-4271.
125. Guantieri V, Venzo A, Di Marco V, Acampora M, Biondi B (2007) Potentiometric and NMR studies on Cd2+ coordination with the histidine-containing Ac184-188NH(2) prion protein fragment. Inorg Chim Acta 360, 4051-4057.
126. Huang XD, Atwood CS, Moir RD, Hartshorn MA, Tanzi RE, Bush AI (2004) Trace metal contamination initiates the apparent auto-aggregation, amyloidosis, and oligomerization of Alzheimer's Abeta peptides. J Biol Inorg Chem 9, 954-960.
127. Brazier MW, Davies P, Player E, Marken F, Viles JH, BrownDR(2008) Manganese binding to the prion protein. J Biol Chem 283, 12831-12839.
128. Martin DP, Anantharam V, Jin H, Witte T, Houk R, Kanthasamy A, Kanthasamy AG (2011) Infectious prion protein alters manganese transport and neurotoxicity in a cell culture model of prion disease. Neurotoxicology 32, 554-562.
129. Hainfellner JA,Wanschitz J, Jellinger K, Liberski PP, Gullotta F, Budka H (1998) Coexistence of Alzheimer-type neuropathology in Creutzfeldt-Jakob disease. Acta Neuropathol 96, 116-122.
130. Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE(2007) Systematic meta-analyses of Alzheimer disease genetic association studies: The AlzGene database. Nature Genet 39, 17-23.
131. Dermaut B, Croes EA, Rademakers R, Van den Broeck M, Cruts M, Hofman A, van Duijn CM, Van Broeckhoven C (2003) PRNP Val129 homozygosity increases risk for early-onset Alzheimer's disease. Ann Neurol 53, 409-412.
132. Riemenschneider M, Klopp N, Xiang W, Wagenpfeil S, Vollmert C, Muller U, Forstl H, Illig T, Kretzschmar H, KurzA(2004) Prion protein codon 129 polymorphism and risk of Alzheimer disease. Neurology 63, 364-366.
133. Kellett KAB, Hooper NM (2009) Prion protein and Alzheimer disease. Prion 3, 190-194.
134. Varela-Nallar L, Toledo EM, Larrondo LF, Cabral ALB, Martins VR, Inestrosa NC (2006) Induction of cellular prion protein gene expression by copper in neurons. Am J Physiol Cell Physiol 290, C271-C281.
135. Rachidi W, Chimienti F, Aouffen M, Senator A, Guiraud P, Seve M, Favier A (2009) Prion protein protects against zinc-mediated cytotoxicity by modifying intracellular exchangeable zinc and inducing metallothionein expression. J Trace Elem Med Biol 23, 214-223.
136. Watt NT, Taylor DR, Kerrigan TL, Griffiths HH, Rushworth JV,Whitehouse IJ, HooperNM(2012) Prion protein facilitates uptake of zinc into neuronal cells. Nat Commun 3, 1-12.
137. Pushie MJ, Pickering IJ, Martin GR, Tsutsui S, Jirik FR, George GN (2011) Prion protein expression level alters regional copper, iron and zinc content in the mouse brain. Metallomics 3, 206-214.
138. Stellato F, Spevacek A, Proux O, Minicozzi V, Millhauser G, Morante S (2011) Zinc modulates copper coordination mode in prion protein octa-repeat subdomains. Eur Biophys J Biophys Lett 40, 1259-1270.
139. Kawahara M, Koyama H, Nagata T, Sadakane Y (2011) Zinc, copper, and carnosine attenuate neurotoxicity of prion fragment PrP106-126. Metallomics 3, 726-734.
140. Spevacek AR, Evans EGB, Miller JL, Meyer HC, Pelton JG, Millhauser GL (2013) Zinc drives a tertiary fold in the prion protein with familial disease mutation sites at the interface. Structure 21, 236-246.
141. Meloni G, Crameri A, Fritz G, Davies P, Brown DR, Kroneck PMH, Vasak M (2012) The catalytic redox activity of prion protein-CuII is controlled by metal exchange with the ZnII-thiolate clusters of zn7metallothionein-3. Chembiochem 13, 1261-1265.
142. Watt NT, Hooper NM (2005) Reactive oxygen species (ROS)-mediated beta-cleavage of the prion protein in the mechanism of the cellular response to oxidative stress. Biochem Soc Trans 33, 1123-1125.
143. Watt NT, Taylor DR, Gillott A, Thomas DA, Perera WSS, Hooper NM (2005) Reactive oxygen species-mediated beta-cleavage of the prion protein in the cellular response to oxidative stress. J Biol Chem 280, 35914-35921.
144. Luo Y, Xu YX, Bao QG, Ding ZC, Zhu CQ, Huang ZX, Tan XS (2012) The alpha and beta domains of human metallothionein-3 co-operatively protect againstAbeta(1-42)-Cu2+cytotoxicity. Chin Chem Lett 23, 1193-1196.
145. Luo Y, Xu YX, Bao QG, Ding ZC, Zhu CQ, Huang ZX, Tan XS (2013) The molecular mechanism for human metallothionein-3 to protect against the neuronal cytotoxicity of Aβ(1-42) with Cu ions. J Biol Inorg Chem 18, 39-47.
146. Schwarzman AL, Goldgaber D, Palha, Buxbaum JD, Saraiva, Frangione,Kelly, Blake, Kirschner, Arvinte, Ciba FDN (1996) Interaction of transthyretin with amyloid beta-protein: Binding and inhibition of amyloid formation. In Nature and Origin of Amyloid Fibrils, JohnWiley & Sons Ltd, Chichester, pp. 146-164.
147. Costa R, Ferreira-da-Silva F, Saraiva MJ, Cardoso I (2008) Transthyretin protects against A-Beta peptide toxicity by proteolytic cleavage of the peptide:Amechanism sensitive to the Kunitz protease inhibitor. PLoS One 3, 1-9.
148. Costa R, Goncalves A, Saralva MJ, Cardoso I (2008) Transthyretin binding to A-Beta peptide-impact on ABeta fibrillogenesis and toxicity. FEBS Lett 582, 936-942.
149. Martinho A, Goncalves I, Cardoso I, Almeida MR, Quintela T, Saraiva MJ, Santos CR (2010) Human metallothioneins 2 and 3 differentially affect amyloid-beta binding by transthyretin. FEBS J 277, 3427-3436.
150. Zatta P, Zambenedetti P, Musicco M, Adorni F (2005) Metallothionein-I-II and GFAP positivity in the brains from frontotemporal dementia patients. J Alzheimers Dis 8, 109-116.
151. Maret W (1995) Metallothionein disulfide interactions, oxidative stress, and the mobilization of cellular zinc. Neurochem Int 27, 111-117.
152. Glaab E, Schneider R (2015) Comparative pathway and network analysis of brain transcriptome changes during adult aging and in Parkinson's disease. Neurobiol Dis 74, 1-13.
153. Holtta M, Minthon L, Hansson O, Holmen-Larsson J, Pike I, Ward M, Kuhn K, Ruetschi U, Zetterberg H, Blennow K, Gobom J (2015) An integrated workflow for multiplex CSF proteomics and peptidomics-dentification of candidate cerebrospinal fluid biomarkers of Alzheimer's disease. J Proteome Res 14, 654-663.
154. Vidal E, Tortosa R, Marquez M, Serafinc A, Hidalgo J, Pumarolaa M (2008) Infection of metallothionein 1+2 knockout mice with Rocky Mountain Laboratory scrapie. Brain Res 1196, 140-150.
155. DabirDV,Trojanowski JQ, Richter-LandsbergC, LeeVM, Forman MS (2004) Expression of the small heat-shock protein alpha B-crystallin in tauopathies with glial pathology. Am J Pathol 164, 155-166.
156. Outeiro TF, Klucken J, Strathearn KE, Liu F, Nguyen P, Rochet JC, Hyman BT, McLean PJ (2006) Small heat shock proteins protect against alpha-synuclein-induced toxicity and aggregation. Biochem Biophys Res Commun 351, 631-638.
157. Wilhelmus MM, Boelens WC, Otte-Holler I, Kamps B, de Waal RM, VerbeekMM(2006) Small heat shock proteins inhibit amyloid-beta protein aggregation and cerebrovascular amyloid-beta protein toxicity. Brain Res 1089, 67-78.
158. Wyttenbach A, Hands S, O'Connor V (2010) Small stress proteins in the central nervous system: From neurodegeneration to neuroprotection, Nova Science Publishers, Inc, Hauppauge.
159. Tortosa R, Vidal E, Costa C, Alamillo E, Torres JM, Ferrer I, Pumarola M (2008) Stress response in the central nervous system of a transgenic mouse model of bovine spongiform encephalopathy. Vet J 178, 126-129.
160. Outero TF, Klucken J, Strathearn KE, Liu F, Nguyen P, Rochet JC, Hyman BT (2006) Small heat shock proteins protect against alpha-synuclein-induced toxicity and aggregation Biochem Biophys Res Commun 351, 631-638.
161. Stetler RA, GanY, ZhangWT, Liou AK, Gao YQ, Cao GD, Chen J (2010) Heat shock proteins: Cellular and molecular mechanisms in the central nervous system. Prog Neurobiol 92, 184-211.
162. Dandoy-Dron F, Guillo F, Benboudjema L, Deslys JP, Lasmezas C, Dormont D, Tovey MG, Dron M (1998) Gene expression in scrapie. Cloning a new scrapie-responsive gene and the identification of increased levels of seven other mRNA transcripts. J Biol Chem 273, 7691-7697.
163. Hanlon J, Monks E, Hughes C, Weavers E, Rogers M (2002) Metallothionein in bovine spongiform encephalopathy. J Comp Pathol 127, 280-289.
164. Pandey KK, Snyder JP, Liotta DC, Musaev DG (2010) Computational studies of transition metal selectivity of octapeptide repeat region of prion protein (PrP). J Phys Chem B 114, 1127-1135.
165. Tougu V, Palumaa P (2012) Coordination of zinc ions to the key proteins of neurodegenerative diseases: A beta, APP, alpha-synuclein and PrP. CoordChemRev 256, 2219-2224.
166. Leal SS, Botelho HM, Gomes CM (2012) Metal ions as modulators of protein conformation and misfolding in neurodegeneration. Coord Chem Rev 256, 2253-2270.
167. Hureau C (2012) Coordination of redox active metal ions to the amyloid precursor protein and to amyloid-beta peptides involved in Alzheimer disease. Part 1: An overview. Coord Chem Rev 256, 2164-2174.
168. Hureau C, Dorlet P (2012) Coordination of redox active metal ions to the amyloid precursor protein and to amyloidbeta peptides involved in Alzheimer disease. Part 2: Dependence of Cu(II) binding sites withAbeta sequences. Coord Chem Rev 256, 2175-2187.
169. Watt AD, Villemagne VL, Barnham KJ (2013) Metals, membranes, and amyloid-beta oligomers: Key pieces in the Alzheimer's disease puzzle? J Alzheimers Dis 33, S283-S293.
170. Bulic B, Pickhardt M, Mandelkow EM, Mandelkow E (2010) Tau protein and tau aggregation inhibitors. Neuropharmacology 59, 276-289.
171. Garcia-Sierra F, Mondragon-Rodriguez S, Basurto-Islas G (2008) Truncation of tau protein and its pathological significance in Alzheimer's disease. J Alzheimers Dis 14, 401-409.
172. Yancopoulou D, Spillantini MG (2003) Tau protein in familial and sporadic diseases. Neuromol Med 4, 37-48.
173. Camponeschi F, Valensin D, Tessari I, Bubacco L, Dell'Acqua S, Casella L, Monzani E, Gaggelli E,Valensin G (2013) Copper(I)-alpha-synuclein interaction: Structural description of two independent and competing metal binding sites. Inorg Chem 52, 1358-1367.
174. Binolfi A, Quintanar L, Bertoncini CW, Griesinger C, Fernandez CO (2012) Bioinorganic chemistry of copper coordination to alpha-synuclein: Relevance to Parkinson's disease. Coord Chem Rev 256, 2188-2201.
175. Breydo L, Wu JW, Uversky VN (2012) A-Synuclein misfolding and Parkinson's disease. Biochim Biophys Acta 1822, 261-285.
176. Pickles S, Vande Velde C (2012) Misfolded SOD1 and ALS: Zeroing in on mitochondria. Amyotroph Lateral Scler 13, 333-340.
177. Kato S, Takikawa M, Nakashima K, Hirano A, Cleveland DW, Kusaka H, Shibata N, Kato M, Nakano I, Ohama E (2000) New consensus research on neuropathological aspects of familial amyotrophic lateral sclerosis with superoxide dismutase 1 (SOD1) gene mutations: Inclusions containing SOD1 in neurons and astrocytes. Amyotroph Lateral Scler 1, 163-184.
178. van der Hilst JCH (2011) Recent insights into the pathogenesis of type AA amyloidosis. ScientificWorldJournal 11, 641-650.
179. Wang LM, Colon W (2007) Effect of zinc, copper, and calcium on the structure and stability of serum amyloid A. Biochemistry 46, 5562-5569.
180. Waelter S, Boeddrich A, Lurz R, Scherzinger E, Lueder G, Lehrach H,Wanker EE (2001) Accumulation of mutant huntingtin fragments in aggresome-like inclusion bodies as a result of insufficient protein degradation. Mol Biol Cell 12, 1393-1407.
181. Fox JH, Kama JA, Lieberman G, Chopra R, Dorsey K, Chopra V, Volitakis I, Cherny RA, Bush AI, Hersch S (2007) mechanisms of copper ion mediated Huntington's disease progression. PLoS One 2, 1-12.